




ISOGENICA VHH BI- AND MULTI-SPECIFIC PLUG-AND-PLAY PLATFORM




- Isogenica's libraries ensure standardised flanking sequences that can be easily slotted into bi- and tri-specific expression cassettes
- Cross-species specific anti-albumin VHH binds to protein A to simplify downstream CMC
- Production in mammalian expression systems and scaled-up purification facilitates developability and functional testing, including T cell activation

[READ THE APPLICATION NOTE](#)

KICKING OFF 2022 WITH NEW DISCOVERY PROJECTS?
GET STARTED WITH A TAILORED BISPECIFICS PROJECT PLAN

Achieve a lead panel of characterised developable VHH binders in a minimum of 16 weeks from project initiation. Coupled with Isogenica multi-specifics plug-and-play platform, establish proof of concept studies reinforced by functional assays efficiently and effectively.

Our discovery projects are headed up by Dr Bill Eldridge and Dr Marion Cubitt who have expertise and experience in the discovery and development of next generation antibody therapeutics. Isogenica has a track record of delivering clinical assets through collaborative partnerships.



LEARN ABOUT APPLICATIONS OF VHH

Copyright © Isogenica 2022 All rights reserved.



Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

